|
|
Article: Immune Response licenses Hybridon's AMPLIVAX vaccine adjuvant.
- Article from:
- BIOTECH Patent News
- Article date:
- October 1, 2003
CopyrightCOPYRIGHT 2003 Biotech Patent News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Immune Response Corporation (Carlsbad, CA) and Hybridon, Inc. (Cambridge, MA) have entered into a license agreement for the use of AMPLIVAX as an adjuvant in the development of a novel vaccine candidate for the prevention and treatment of HIV, the virus that causes AIDS. The new vaccine candidate, which has already demonstrated activity in laboratory experiments, combines the whole-killed vaccine technology employed in REMUNE, an immune-based HIV therapeutic vaccine being evaluated in Phase II clinical trials by The Immune Response Corporation, plus AMPLIVAX, Hybridon's 2nd generation immunomodulatory oligonucleotide (IMO) adjuvant designed to enhance the immune ...